Daiichi Sankyo

Japanese firm Daiichi wants to go alone in search of targeted cancer drugs

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and was the top-selling ADC globally in 2023

Malaysia's IHH Healthcare unit sues Japan's Daiichi Sankyo over Fortis deal

On Oct, 16, Northern TK Venture filed a claim against the Japanese pharmaceuticals manufacturer stating it caused losses to the company by preventing it from proceeding with open offers

Singh brothers get 6-month jail term in Fortis-Daiichi Sankyo case

Former Ranbaxy promoters Malvinder Singh and Shivinder Singh are accused of concealing information about wrongdoing at Ranbaxy during its sale of a majority stake to Daiichi Sanyo, in 2008

Sun Pharma to acquire 11.28 pc stake in Zenotech from Daiichi Sankyo

Sun Pharma said it will pay Rs 5.32 crore for the stake

Fortis parent IHH sued by US fund Emquore for $6.5 bn over 2018 takeover

IHH acquired a 31 per cent controlling stake in Fortis Healthcare in 2018 following a prominent bidding war against domestic and international companies.

AstraZeneca agrees to pay Japan's Daiichi $6 bn for new cancer drug

The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said

Amid Daiichi-Ranbaxy row, Delhi HC restricts sale of 'SRL' trademark

The HC has been hearing Daiichi's petition seeking the implementation of Rs 3,500 cr Singapore tribunal arbitral award passed in its favour, against former promoters of Fortis Healthcare

Top headlines: Consumer spend, Singh bros, Essar Steel case, and more

From NSO data on consumer spending to Walmart International's sales growth, here are the top news stories that made headlines today

SC holds Malvinder, Shivinder guilty of contempt in Daiichi Sankyo case

Daiichi Sankyo has alleged the brothers created encumbrances on 1.2 million shares of Fortis in violation of court orders

Malvinder, Shivinder settlement talk with RFL runs into trouble

Japanese drug major Daiichi Sankyo has been fighting a prolonged legal battle with the Singh brothers

How the Daiichi CEO capped a $37 billion recovery with a cancer drug deal

The stock was in the middle of a six-year free fall, its Indian subsidiary Ranbaxy Laboratories Ltd. was banned by the US from selling products there

SC asks Singh brothers to come up with plan to pay Daiichi Rs 3,500 cr

Top court gives Singh brothers time till March 28; says their presence in court 'not good for country's honour'

How will you pay Rs 3,500 cr to Daiichi Sankyo: SC asks Singh brothers

The SC bench asked Malvinder and Shivinder Singh to appear before it on March 28 and submit a plan

Daiichi Sankyo case: Supreme Court summons Singh brothers on March 14

SC observed it would like to hear the Singh brothers to know their explanation of the various undertakings they had given to Daiichi Sankyo

Daiichi Sankyo case: Singh brothers may move Supreme Court of Singapore

Family members working overtime to settle tiff between the two out of court

Daiichi Sankyo case: Setback for Singh brothers in Singapore court

Daiichi has convinced an Indian court to halt the sale of another firm founded by the Singhs

Singh brothers question Daiichi allegations of misrepresentation in HC

Senior advocate Harish Salve, appearing on behalf of Malvinder and Shivinder Singh told the Delhi High Court on Wednesday that Daiichi Sankyo had full knowledge of all affairs of Ranbaxy Laboratories while purchasing stake in the company in 2008. Highlighting an extensive series of e-mails between several members of Daiichi's top brass during the time of the negotiations, Salve told the court that the Japanese pharmaceutical major's claims of misrepresentation of critical information about the internal issues of Ranbaxy was merely a farce to now extract unjustified reparations from the Singh brothers. "Even after having the knowledge of the situation, Daiichi bought the company nonetheless. Now they (Daiichi) make tall claims of misrepresentation. These (Daiichi's senior management) are hardened negotiators, not simpletons being mislead in any manner," said Salve in court.In support of this stance, the lawyer for the former Ranbaxy promoters also showed the court that Daiichi chose ..

Daiichi protests Singhs' Religare Health Insurance stake sale in court

Daiichi Sankyo approached the Delhi High Court on Monday to protest against the 80 percent stake sale of Religare Health Insurance by former Ranbaxy promoter's Malvinder and Shivinder Singh. The objection to the April 9 sale of Religare's insurance business with private equity fund True North Managers marks Daiichi's latest attempt at securing the assets of the Singh brothers for the realisation of a Rs 2,562 crore Singapore arbitration award in favour of the Japanese pharmaceutical major. Senor advocate C A Sundaram began Monday's proceedings by claiming that the former Ranbaxy promoters had, by conducting the Rs 1,300 stake sale, brazenly violated the court's earlier orders which had directed them to apply to court before transferring any of their unencumbered assets on March 6. Highlighting the history of the case, Sundaram mentioned that Daiichi had from the very beginning, questioned of the activities of the Singh brothers and their ability to pay for the arbitral award. "Time ...

Daiichi seeks external auditor to scrutinise Singh brothers' assets

Daiichi Sankyo approached the Delhi High Court on Wednesday, pressing for the appointment of an external auditor to scrutinise the assets of former Ranbaxy promoters Malvinder Singh and Shivinder Singh. The application seeks to conclusively determine, whether the Singh brothers are in a position to pay the Rs 2,562 crore Singapore arbitration award in favour of the Japanese pharmaceutical major. Wednesday's move follows Daiichi's allegations of false asset declarations made by the Singh brothers on affidavit, when compared to auditor reports of their holding company (RHC Holdings) and other relevant sources. Claiming a Rs 1,500 discrepancy in the figures, Daiichi has stated that a majority of the former Ranbaxy promoters' assets are unrealisable, encumbered and of related and unlisted parties. The Japanese company has also mentioned that this discrepancy is contrary to express undertakings made by the Singh brothers that two of their companies (RHC Holdings and Oscar Investments) had .

HC asks Singh brothers to reply to Daiichi plea

It cost Daiichi $500 million to settle up with the US agencies in 2013